Introduction: Schedule Y of the Drugs and Cosmetics Rules is the principal regulatory framework governing clinical trials in India. This blog presents focused multiple-choice questions designed for M.Pharm students to deepen understanding of Schedule Y provisions, regulatory responsibilities, documentation, trial phases, safety reporting and post‑marketing surveillance. The questions emphasize practical interpretation of sponsor and investigator obligations, ethics committee roles, trial registration, import permissions and bioequivalence requirements, reflecting expectations in academics and regulatory practice. Use these MCQs for revision and self-assessment to strengthen knowledge needed for designing, conducting and evaluating clinical research compliant with Indian regulations and international Good Clinical Practice principles.
Q1. Which legal instrument contains Schedule Y governing clinical trial requirements in India?
- Drugs and Cosmetics Rules, 1945
- Indian Medical Council Act
- Food Safety and Standards Act
- Pharmaceuticals and Medical Devices Rules
Correct Answer: Drugs and Cosmetics Rules, 1945
Q2. Which authority grants permission to conduct clinical trials of new drugs in India?
- State Drug Controller
- Drug Controller General of India (DCGI)
- Indian Council of Medical Research (ICMR)
- Central Bureau of Investigation (CBI)
Correct Answer: Drug Controller General of India (DCGI)
Q3. Schedule Y requires that clinical trials be conducted in compliance with which standard?
- Good Manufacturing Practice (GMP)
- Good Clinical Practice (GCP)
- Good Laboratory Practice (GLP)
- Good Distribution Practice (GDP)
Correct Answer: Good Clinical Practice (GCP)
Q4. Which document provides comprehensive clinical and non‑clinical data about an investigational product for investigators?
- Investigator’s Brochure (IB)
- Study Protocol
- Informed Consent Form (ICF)
- Case Report Form (CRF)
Correct Answer: Investigator’s Brochure (IB)
Q5. Where must a clinical trial in India be registered before enrolling the first participant?
- Clinical Trials Registry – India (CTRI)
- US ClinicalTrials.gov
- European EudraCT
- WHO Global Database only
Correct Answer: Clinical Trials Registry – India (CTRI)
Q6. Which body provides ethical review and approval at the site level for clinical trials under Schedule Y?
- Institutional Ethics Committee (IEC)
- Drug Controller General of India (DCGI)
- Indian Council of Medical Research (ICMR)
- Central Ethics Authority
Correct Answer: Institutional Ethics Committee (IEC)
Q7. Which phase of clinical development under Schedule Y primarily assesses preliminary efficacy and dose response in patients?
- Phase I
- Phase II
- Phase III
- Phase IV
Correct Answer: Phase II
Q8. Which phase is mainly focused on initial safety, tolerability and pharmacokinetics, usually in healthy volunteers?
- Phase I
- Phase II
- Phase III
- Phase IV
Correct Answer: Phase I
Q9. According to Schedule Y, bioavailability/bioequivalence studies are most often required for which type of application?
- New chemical entity (innovator) seeking global approval
- Generic formulations seeking marketing approval
- Vaccines developed in public health programs
- Traditional herbal proprietary products
Correct Answer: Generic formulations seeking marketing approval
Q10. Which authority issues import permission for investigational medicinal products to be used in clinical trials in India?
- State Drug Controller
- Central Drugs Standard Control Organization (CDSCO)/DCGI
- Director General of Foreign Trade
- Ministry of Finance
Correct Answer: Central Drugs Standard Control Organization (CDSCO)/DCGI
Q11. What is the minimum document retention period recommended under Schedule Y after trial completion for essential trial records?
- At least 2 years after trial completion
- At least 5 years after trial completion
- At least 10 years after trial completion
- No specific retention period is mentioned
Correct Answer: At least 5 years after trial completion
Q12. Who is primarily responsible for obtaining informed consent from trial participants under Schedule Y?
- Sponsor’s clinical operations team
- Principal Investigator/Investigator
- Regulatory authority representative
- Institutional administrator
Correct Answer: Principal Investigator/Investigator
Q13. Which of the following is NOT typically an essential document maintained at an investigator’s site under Schedule Y?
- Study Protocol
- Investigator’s Brochure
- Case Report Forms
- New Drug Application (NDA)
Correct Answer: New Drug Application (NDA)
Q14. How does Schedule Y define a Serious Adverse Event (SAE) in the context of clinical trials?
- An event that is expected and non‑serious
- An event that results in death, is life‑threatening, requires hospitalization, results in disability or congenital anomaly
- An event of mild local irritation only
- An administrative protocol deviation
Correct Answer: An event that results in death, is life‑threatening, requires hospitalization, results in disability or congenital anomaly
Q15. According to ICH-aligned reporting timelines adopted in Schedule Y practice, what is the standard timeline for SUSAR reporting to regulatory authorities?
- No specific timeline is required
- 7 days for fatal or life‑threatening SUSARs and 15 days for other SUSARs
- 30 days for all SUSARs
- Within 6 months after trial completion
Correct Answer: 7 days for fatal or life‑threatening SUSARs and 15 days for other SUSARs
Q16. Under Schedule Y, when can a waiver of local clinical or BE studies be considered for global clinical data?
- When the sponsor requests without justification
- When a waiver is granted by DCGI based on adequate foreign data
- Waivers are never permitted under Schedule Y
- Only when trials are conducted in Europe
Correct Answer: When a waiver is granted by DCGI based on adequate foreign data
Q17. Which of the following best describes the sponsor’s responsibilities under Schedule Y?
- Only to provide the investigational product
- Designing the study, funding, regulatory submissions, and overall quality and safety oversight
- Only to recruit study participants
- Only to approve the informed consent form
Correct Answer: Designing the study, funding, regulatory submissions, and overall quality and safety oversight
Q18. The Trial Master File (TMF) should contain which types of documents as essential for inspection under Schedule Y?
- Copies of ethics approvals and signed contracts/agreements and essential documents
- Only monitoring visit expense reports
- Only manufacturing batch records unrelated to the study
- Only marketing materials for the product
Correct Answer: Copies of ethics approvals and signed contracts/agreements and essential documents
Q19. What is the primary purpose of conducting a bridging study as contemplated in Schedule Y?
- To confirm Good Manufacturing Practice compliance
- To extrapolate and confirm foreign clinical data in the Indian population
- To evaluate packaging stability only
- To replace Phase III trials entirely
Correct Answer: To extrapolate and confirm foreign clinical data in the Indian population
Q20. What is the main objective of Phase IV (post‑marketing) studies under Schedule Y?
- Initial assessment of safety in a few volunteers
- Monitor long‑term safety and effectiveness in the general population
- Conduct dose escalation in healthy subjects
- Demonstrate bioequivalence for generic approval
Correct Answer: Monitor long‑term safety and effectiveness in the general population
